



ASAS/EULAR 2022 axSpA Guidelines¹


Phase 1



Phase 2



Phase 3




Algorithm based on the ASAS-EULAR recommendations for the management of axSpA. See Ramiro S et al¹ for additional information about citations in figure.
 Ab=Antibody; ASAS=Assessment of SpondyloArthritis International Society; ASDAS=Ankylosing Spondylitis Disease Activity Score; axSpA=Axial Spondyloarthritis; bDMARD=Biological Disease-Modifying Antirheumatic Drug; EULAR=European Alliance of Associations for Rheumatology; IBD=Inflammatory Bowel Disease; IL-17i=Interleukin-17 Inhibitors; JAKi=Janus Kinase Inhibitors; NSAID=Non-Steroidal Anti-inflammatory Drug; TNFi=Tumour Necrosis Factor Inhibitors.

1. Ramiro S, et al. *Ann Rheum Dis.* 2023;82(1):19-34.




ACR/SAA/SPARTAN 2019 axSpA Guidelines¹


1st Line Therapy*



2nd Line Therapy*



3rd Line Therapy*



***General Adjunctive Management:** unsupervised back exercises, formal group or individual self-management education, fall evaluation/ counselling. Monitor using validated axSpA disease activity measures, & CRP or ESR regularly. Adjunctive management is intended to occur at all stages (from top to bottom of flow figure).

***Against using treat-to-target strategy** with target of ASDAS <1.3 or 2.1 over strategy based on provider assessment; against obtaining repeat spine radiographs at a scheduled interval

Legend

- Strongly recommended
- Conditionally recommended
- Conditionally recommended against
- Strongly recommended against

¹See Figure 1B in Ward et al 2019.¹

ACR=American College of Rheumatology; APR=Apremilast; ASDAS=Ankylosing Spondylitis Disease Activity Score; axSpA=Axial Spondyloarthritis; CRP=C-Reactive Protein; ESR=Erythrocyte Sedimentation Rate; GC(s)=Glucocorticoid(s); IBD=Inflammatory Bowel Disease; IXE=Ixekizumab; LEF=Leflunomide; MRI=Magnetic Resonance Imaging; MTX=Methotrexate; NSAID(s)=Nonsteroidal Anti-inflammatory Drug(s); PAM=Pamidronate; PICO=Population, Intervention, Comparison, Outcomes; SAA=Spondylitis Association of America; SEC=Secukinumab; SPARTAN=Spondyloarthritis Research and Treatment Network; SSZ=Sulfasalazine; THL=Thalidomide; TNFi=Tumor Necrosis Factor Inhibitor; TOF=Tofacitinib.

1. Ward MM, et al. *Arthritis Rheumatol.* 2019;71(10):1599-1613.

